Skip to main content

Table 2 Sensitivity of five screening questions together with their composite for epilepsy

From: High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20 years of community directed treatment with ivermectin

Question Number with positive response (%) Number confirmed with epilepsy (%) Sensitivity (95% CI)
Q1a. Lost consciousness and experienced loss of bladder control 75 (30.7) 51 68.0 (54.2–78.8)
Q1b. Lost consciousness and experienced foaming in the mouth 61 (25.0) 49 80.3 (70.1–90.6)
Q2. Experienced absence or sudden loss of contact with the surroundings for a short duration of time 152 (61.9) 103 67.8 (60.2–75.3)
Q3. Experienced sudden, uncontrollable twitching or shaking of arms, legs or head for few minutes 119 (48.8) 69 58.0 (49.0–67.0)
Q4. Experienced sudden and brief bodily sensations, seen or heard things that were not there, or smelt strange odours 76 (31.15) 36 47.4 (35.9–58.9)
Q5. Ever been diagnosed with epilepsy 110 (44.26) 95 86.4 (79.8–92.9)